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Abstract  
Introduction: The availability of over-the-counter (OTC) medicines containing codeine has generated worldwide 
debate with increased focus on its safe use. Medicine agencies across the European Union (EU) have responded 
to the public health concern by placing restrictions and warnings on codeine medicines sold OTC in high street 
and internet pharmacies. These restrictions include direct-to-consumer advertising, however there are few 
published studies examining conditions of advertising across member states. 
Methods: A review of the conditions of advertising was conducted by accessing information pertaining to each 
medicines regulatory agency allowing the sale of codeine in the EU. Each agency was asked to respond to three 
questions and data were collated and tabulated in Excel to demonstrate its position on OTC codeine advertising.  
Results:  In the EU, 12 countries allow the sale of OTC codeine, while 16 do not. Of the 12 countries permitting 
its sale OTC, 4 countries prohibited direct-to-consumer advertising of codeine. The majority of the countries 
permitting advertisements did not have any additional or special restrictions or warnings for codeine-containing 
products with the exception of the UK where advertising codeine was only permitted under certain restrictions 
including product endorsement and special warnings including its indication of use for a maximum of three 
days.    
Conclusion: There is wide disparity in advertising of OTC codeine in the EU. Safeguards for OTC codeine use 
are likely to continue to remain a priority in the interest of public safety. 
Key points  
• There is wide disparity in the direct-to-consumer advertising of codeine sold over-the-counter (OTC) 
across the EU 
• Countries allowing direct-to-consumer advertising may not effectively communicate the risk of 
developing a substance use disorder (SUD) due to codeine use 
• Research is needed to examine the conditions of sale of OTC codeine and its relationship to developing 
a SUD  
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1.0 Introduction 
The availability of over-the-counter (OTC) medicines containing codeine has generated worldwide debate with 
increased focus on its safe use (1-3). Data on codeine use and misuse across the EU remains scant and confined 
to French and Norwegian studies with some statistics available on SUD treatment in the UK and Ireland (4-7).  
In the UK in 2013-2014, 2.2% of individuals attending specialist addiction treatment services did so for codeine. 
In Ireland over a defined 5-year period, 1.7% of all people attending treatment did so for codeine.  
Codeine is an appropriate medicine used in the short term treatment of mild-to-moderate pain; however, due to 
risk of developing an addiction, use for chronic pain in the longer term may result in the consumption of higher 
than recommended doses for longer than is medically advisable (8). There is also risk of harmful effects 
resulting from prolonged or over use of paracetamol, ibuprofen and aspirin contained in many combination 
codeine products (9-11).  The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM 
V) currently defines ‘addiction’ under the term substance use disorder (SUD). Under this term the diagnosis of 
an SUD is based on a set of behaviours related to the use of that substance and falls into four main categories. 
These categories included impaired control, social impairment, risky use and pharmacological indicators such as 
tolerance and withdrawal.     
National medicine agencies across the European Union (EU) have responded to the public health concern by 
placing restrictions and warnings on codeine medicines sold OTC in high street and internet pharmacies. These 
restrictions include the availability of codeine for self-selection (without requesting it directly from the 
pharmacist), limits on quantities purchased in a single transaction and drug potency (12). Previous research in 
2015 has shown that 12 of the 28 EU member states allowed the sale of OTC codeine in solid dosage form 
(Bulgaria, Cyprus, Denmark, Estonia, Ireland, Latvia, Lithuania, Malta, Poland, France, Slovenia and the United 
Kingdom) and two countries (the Netherlands and Hungary) as a codeine cough linctus only. Denmark was the 
only member state allowing the sale of OTC codeine in supermarkets and convenience stores (behind the 
counter).  
Recently, direct-to-consumer advertising of OTC codeine has come under the spotlight as having the potential to 
influence buying behaviour (2). Advertising of medicine is defined in medical law as “any form of door to door 
information, canvassing activity or inducement designed to promote the prescription, supply, sale or 
consumption of medicinal products”(13). This specifically includes advertising to the general public, supply of 
samples, inducements to prescribe or supply by the gift, offer or promise of a bonus, monetary remuneration in 
any form, and sponsorships including travel or accommodation associated with medical conferences or medicine 
selling.  
Direct-to-consumer advertising of OTC medicines remains controversial (14, 15). Some argue it is specifically 
designed to convince the consumer that the product is worth buying and will have a beneficial effect on health, 
with opponents claiming it misleads consumers into buying drugs they may not necessarily need or want.  
Counter claims to the debate argue that advertising of OTC medicines add a highly valued source of information 
to allow consumers to make informed decisions about self-care for pain relief (15).   
Direct-to-consumer advertising of prescription drugs is illegal in the EU. However, it is suggested that 
consumers often access online content and view branded drug websites in the United States and New Zealand 
where direct-to-consumer advertising of prescription drugs is legal (16).   
To date there has been limited research examining regulatory conditions related to the advertising of OTC 
medicines containing codeine to the public across the EU. The aim of this study was to describe the regulatory 
position on the advertising of codeine for sale OTC in each of the EU member states permitting its sale to the 
public without a medical prescription, specifically to (i) identify which countries allowed direct advertising of 
OTC medicines containing codeine and (ii) if the harms imposed by codeine consumption were adequately 
communicated and aimed to prevent unnecessary patient exposure to risk of developing a SUD. 
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2.0 Methods 
Data were collected between September 2017 and February of 2018. Initially, current regulation on the sale of 
OTC codeine was established for each of the EU member states. First, the website of each of the relevant 
medicines agencies was searched over a 2 week period at the beginning of the study. Each website was screened 
using the English language option. The objective of the web search was to establish if codeine was permitted for 
sale OTC and to check for information relating to the advertising of OTC medicines. Second, agencies were 
contacted by e-mail to obtain specific information related to direct-to-consumer advertising of codeine. 
Medicines agencies not responding by e-mail within a 6-week time frame (Denmark, France, Bulgaria and 
Slovenia) were followed up by telephone call by one of the research team members. All medicines agencies 
made a reply giving a 100% response rate. 
A topic guide was devised to guide the data collection and to ensure that comparisons could be made. Three 
subject areas were included:   1) Level and type of restrictions placed on all forms of direct-to-consumer 
advertising of OTC medicines containing codeine. 2) Labelling criteria on packaging including indication 
related to the risk of addiction and any other patient information specific to codeine.  3) Complaints received by 
the medicines agency related to direct consumer advertising of OTC medicines containing codeine. 
Data were collated and summarised and entered into an Excel® spreadsheet.  Two members of the research 
team independently tabulated the data under each of the three main questions. The content of this information 
was discussed, crosschecked and agreed before compiling into two tables (17). A third member of the research 
team checked the content of the final table and reviewed the data against the written content received by eleven 
of the twelve countries. One country (Bulgaria) had not provided a written response so verbal responses noted 
by the researcher were checked in this case.  
3.0 Results 
3.1 Conditions of codeine advertising across the EU 
Table 1 shows the permitted sales of OTC codeine medicines in the EU. Recent rescheduling of codeine has 
occurred in two European countries. In 2015 Hungary removed the sale of codeine cough mixture for sale 
without a medical prescription and in 2017 France restricted codeine to prescription only (18). Twelve countries 
allow the sale of OTC codeine, while 16 do not. Table 2 shows the conditions of advertising, packaging 
requirements of OTC codeine and if complaints were received by the medicine agency. Of the 12 countries 
permitting its sale OTC, 4 countries prohibited direct-to-consumer advertising of codeine. All countries 
highlighted that direct-to-consumer advertising of medicines was stipulated in the countries Medicines Act. 
The majority of the countries permitting advertisements did not have any additional or special restrictions or 
warnings for codeine-containing products with the exception of the UK where advertising codeine was only 
permitted under certain restrictions relating to product endorsement and special warnings, including its 
indication of use for a maximum of 3 days.   Equally, the UK was the only country stipulating advertising 
warnings with respect to the risk of developing an addiction.   The Medicines and Healthcare products 
Regulatory Agency (MHRA) in the UK was the only agency indicating advertising complaints made by 
members of the public. This was related to two OTC codeine products, Syndol® and Solpadeine® Max.  It was 
claimed that promotional materials for Syndol® were inadequate and the latter complaint relating to Solpadeine 
®Max suggested that warnings around use of codeine were not clearly presented.  In both cases the MHRA did 
not uphold the complaint, however did make recommendations resulting in changes to advertising of both 
products.   
4.0 Discussion 
The study found wide disparity in direct-to-consumer advertising of OTC codeine across the EU. It is likely that 
countries banning the advertising of codeine perceive the risks to be greater than those that did not, including the 
potential for consumers to develop a SUD from inappropriate codeine use. For some countries like Denmark and 
the UK, allowing direct-to-consumer advertisement may hold the opposite viewpoint, either that adequate 
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structures are already in place to prevent excessive use, or that the levels of codeine contained in OTC 
formulations are too small to induce a SUD (2).  
Across EU member states, there appears to be a lack of evidence to evaluate the effects of codeine advertising 
on consumers decision to purchase , consumption patterns or levels of SUD. However, television advertisements 
are considered to be an important promotional tool on potential buyers of medicines, particularly analgesics. 
Non-opioid analgesics are some of the most popular OTC medicines purchased across Europe and studies have 
shown that television advertising has a significant impact on purchase decisions (15).  Marketing strategies such 
as that adopted by Purdue Pharma ® for promoting OxyContin® directly to doctors was shown to play a huge 
role in the opioid epidemic in the United States (19). The concern would be that promoting codeine directly to 
the public through any form of advertisement may play a role in medicine use and subsequently development of 
a SUD. Additionally, online promotional advertising of prescription medicines accessible globally presents 
additional challenges for national regulatory agencies not permitting direct-to-consumer advertising of 
medicines either prescription or OTC.  While traditional print and broadcast media can be controlled to a certain 
extent, online promotions have the ability to cross national boundaries through various media platforms to 
countries when it is not legal (16).   
Of the countries allowing direct-to-consumer advertising, the UK appear to be the most comprehensive in 
communicating risk of developing an addiction  in advertising materials to the public, although some complaints 
were received. While the impact of such communication remains unquantifiable, other countries permitting 
direct-to-consumer advertising should consider improvements in communication to highlight the risks of SUD 
in the interest of public health. Studies have shown that content contained in advertisements can change 
perceptions surrounding the drug’s efficacy, risk and benefit (20). The current study did not review if the 
advertisements met the conditions of the competent authorities and while it was stipulated that all advertising 
materials must be comprehensive, valid and include information like the product name, active ingredients, 
adverse drug reactions, precautions and contraindications, it is likely that inclusions of  health warnings on 
packaging and improvements in  patient-information leaflets (PILs) could further educate the public on safe use 
and potential risk of SUD. It should be noted that all medicines must, under EU regulation, include PILs 
providing information on the safe and appropriate use of the medicine. However, studies have shown that 
patients’ often fail to read and/or understand the information provided in the PIL (21). It is also important in the 
future to establish if direct sale of OTC codeine in countries with fewer restrictions of sale correlate with 
national figures for codeine-specific SUD, adverse drug reactions, intoxication and mortality. Codeine 
consumption resulting in SUD is now recognised around the world as a serious problem (22) and shows the 
importance of reviewing and challenging current regulation. From the perspective of drug safety and risk 
management, it is important to investigate fully the impact of codeine advertising on developing a SUD. 
One of the limitations of the study is that it did not evaluate the advertising materials from the eight countries 
permitting the advertising of codeine OTC. Therefore we are unable to comment directly on the content of 
advertising in each member state. All countries were accessed in the English language and there is some 
possibility that information could have been lost through translation other relevant information may have been 
available published in the local language.  However all responses given by the competent authority in each 
country were done through the English language.       
5.0 Conclusions 
The condition of sale and advertising of OTC codeine and its association with developing a SUD is likely to 
remain a subject of popular debate into the future. Safeguards are likely to continue to remain a priority in the 
interest of public safety in many EU member states and worldwide. Strengthening medicine safety is a key 
priority for the European Medicines Agency and direct-to-consumer advertising of codeine in countries allowing 
its sale without direct medical supervision needs to be further examined to ensure it is adequate and is not 
placing consumers at increased harm. 
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Table 1: Sale of over-the-counter codeine-containing medicines according to EU member states 
Country  National Competent Authorities Permitted to sell medicines 
containing codeine over-the-
counter without a medical 
prescription (Yes/No) 
 
Austria Austrian Agency for Health and Food No 
Belgium 
 
Federal Agency for Medicine and Health products No 
Bulgaria 
 
Bulgarian Drug Agency  Yes 
Croatia Agency for Medicinal Products and Medical Devices of Croatia  No 
Cyprus Ministry for Health Yes 
Czech Republic 
 
State Institute for Drug Control No 
Denmark Danish Medicines Agency  Yes 
Estonia State Agency of Medicines  Yes 
Finland Finnish Medicines Agency  No 
France French National Agency of Medicine and Health Products Safety  No 
Germany  Federal Agency for Drug and Medical Devices  No 
Greece National Organisation for Medicines  No 
Hungary 
 
National Institute for Pharmacy No 
Ireland  Health Products Regulatory Authority  Yes 
Italy Italian Medicines Agency No 
Lativa  State Agency of Medicines of the Republic of Latvia Yes 
Lithuania The State Medicines Control Agency of Lithuania Yes 
Luxembourg Ministry of Health No 
Malta 
 
Medicines Authority of Malta  Yes 
 
Netherlands Medicines Evaluation Board Yes (Cough linctus only) 
Poland Main Pharmaceutical Inspectorate Yes 
Portugal National Authority of Medicines and Health Products No 
Romania National Agency for Medicines and Medical devices  No 
Slovakia State Institute for Drug Control  No 
Slovenia Agency for Medicinal products and Medical devices of the Republic of 
Slovenia  
Yes 
Spain Spanish Agency for Medicines and Health products  No 
Sweden Medical Products Agency  No 
United Kingdom Medicine and Healthcare products Regulatory  
Authority  
Yes 
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Table 2. Conditions of advertising for over-the-counter (OTC) codeine-containing medicines 
 
 
 
 
Country permitting 
sale of OTC codeine 
Permitted 
direct to the 
consumer 
advertising 
of medicines 
containing 
codeine OTC 
without a 
medical 
prescription 
 
Advertising conditions for OTC codeine sales Packaging 
requirements related 
to risk of addiction 
Advertising 
complaints 
received  
Bulgaria 
 
Yes Advertising of codeine is permitted for OTC combination 
products.  Expert council of advertising draws expertise on the 
advertising of medicines and all advertisements and promotions 
must be approved by the Bulgarian Drug Agency (BDA). The 
BDA monitors pharmaceutical promotion of OTC drugs 
No requirement to 
include any special 
warning indicating the 
risk of addiction 
None 
Cyprus No    
Denmark Yes Advertising is permitted for OTC codeine and must comply with 
rules for advertising of medicine stipulated in the Danish 
Medical Act (2014). Advertisements must be comprehensive and 
valid and cannot be misleading or exaggerate the abilities of the 
medicine  
Packaging does not 
need to carry a label 
indicating the risk of 
addiction or any 
additional special 
warnings  
None 
Estonia Yes Advertising is permitted and must comply with the Medicinal 
Products Act of Estonia, Chapter 4 Division 1. Advertising of the 
product to the general public must contain sufficient information 
for the correct and safe use of the product 
No requirement for 
labelling or warnings 
with respect to 
codeine addiction  
None 
Ireland  No    
Lativa  No    
Lithuania Yes Advertising of OTC codeine is not prohibited according to the 
Law on Pharmacy of Lithuania. Must follow the general rules 
outlined for advertisement of medicines to the general public 
No special 
requirements on 
packaging  
None 
Malta 
 
Yes 
 
Medicine containing codeine may be advertised to the general 
public by virtue of their composition and purpose and in line 
with regulation (2005). The advertisement should not be 
misleading and encourage the rational use of medicine by 
presenting it clearly and objectively   
No special 
requirements  
None 
Netherlands Yes (Cough 
linctus only) 
Advertisements must be in accordance with the Dutch Medicines 
Act and code for pharmaceutical advertising (CGR) that governs 
the advertising of medical products to the public. They must 
contain the name of the product and the information necessary 
for correct use of the medicine  
There are no special 
warnings on the label 
required to illustrate 
the risk of addiction. 
However it is 
mentioned in the 
Patient Information 
Leaflet (PIL) 
None 
Poland No    
Slovenia Yes Medicines containing codeine available without a prescription in 
Slovenia have no restrictions regarding advertising to the public. 
Advertising must contain sufficient information for correct and 
safe use 
No requirements to 
carry additional 
warnings of addiction  
None 
United Kingdom Yes 
 
Permitted to advertise codeine under restriction and all 
advertising materials must be submitted and approved by the 
Proprietary Association of Great Britain. Advertisements of 
codeine cannot appear to exaggerate the abilities of the medicine 
or appear to be endorsed by a healthcare professional  
Labelling and 
packaging must 
adhere to contain 
conditions. Must 
indicate that the 
medicine is for 3 days 
use only and can 
cause addition. 
Straplines must not 
refer to the power or 
strength of the 
medicine. Packaging 
materials must also 
host a critical health 
panel. This panel 
provides information 
for self-assessment of 
symptoms and signs 
of addiction 
Two complaints 
received by the 
Medicines and 
Healthcare 
products 
Regulatory Agency 
(MHRA) regarding 
the advertisement 
of OTC codeine  
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